New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT04425018
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This study tests whether a newer drug, Margetuximab, works better than the standard drug Trastuzumab when combined with chemotherapy and another targeted therapy before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two drug combinations, and the main goal is to see which group has no cancer left at surgery. This is a phase 2 trial, so it's still being tested for effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine Medical Center
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber at South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
UPMC Hillman Cancer Center - Arnold Palmer at Mountain View
Greensburg, Pennsylvania, 15601, United States
-
UPMC Hillman Cancer Center - Arnold Palmer at Norwin
Irwin, Pennsylvania, 15642, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.